FDA-cleared profile

uCT 780

Shanghai United Imaging Healthcare Co., Ltd. · CT/CTA · FDA-cleared (510(k))

Authorized purpose: uCT 780 produces whole-body cross-sectional CT images, including head, neck, cardiac, and vascular imaging, supports protocol-governed low-dose lung cancer screening and dual-energy material visualization, and uses DELTA deep-learning reconstruction for adult head, chest, abdomen, cardiac, and vascular applications.

Clinical role
Acquires and reconstructs CT examinations, applies DELTA at one of five noise-reduction levels, and supports dual-energy analysis by combining low- and high-energy acquisitions of the same anatomy to visualize material or chemical information and multiple-energy images.
Images and patients
CT/CTA · Multi-region
Key limitation
Keep in mind: The FDA summary states that the submitted clinical study alone cannot support promotional claims that DELTA achieves equivalent or better image quality; additional testing is needed for such claims. A radiologist and physicist should determine appropriate dose for each diagnostic task, only clinicians or dosimetrists should reduce dose, and DELTA was not thoroughly tested in pediatric patients. Low-dose lung cancer screening must follow an approved and published screening program.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: uCT 780 produces whole-body cross-sectional CT images, including head, neck, cardiac, and vascular imaging, supports protocol-governed low-dose lung cancer screening and dual-energy material visualization, and uses DELTA deep-learning reconstruction for adult head, chest, abdomen, cardiac, and vascular applications.
  • Which images or clinical context are in scope?Modality: CT/CTA Anatomy or clinical context: Multi-region Input: CT projection data acquired on uCT 780; uWS-CT-Dual Energy Analysis accepts United Imaging CT images of the same anatomy acquired at different tube voltages and currents.
  • Who uses it?Intended users: A consultation with a radiologist and a physicist should be made to determine the appropriate dose to obtain diagnostic image quality for the particular clinical task; clinicians or dosimetrists should only be allowed to reduce patient dose in clinical practice.
  • What does the software produce?Output: Cross-sectional CT images reconstructed with FBP or DELTA and dual-energy material, chemical, and multiple-energy visualizations for qualified-user review.
  • What is its most important limitation?Key limitation: The FDA summary states that the submitted clinical study alone cannot support promotional claims that DELTA achieves equivalent or better image quality; additional testing is needed for such claims. A radiologist and physicist should determine appropriate dose for each diagnostic task, only clinicians or dosimetrists should reduce dose, and DELTA was not thoroughly tested in pediatric patients. Low-dose lung cancer screening must follow an approved and published screening program.

Clinical takeaway. Clinical role: uCT 780 produces whole-body cross-sectional CT images, including head, neck, cardiac, and vascular imaging, supports protocol-governed low-dose lung cancer screening and dual-energy material visualization, and uses DELTA deep-learning reconstruction for adult head, chest, abdomen, cardiac, and vascular applications.

Evidence takeaway. Evidence from the reviewed source record: FDA-reviewed manufacturer evidence includes phantom testing and a 60-subject, two-reader clinical image-quality program with separated training, validation, and test data. The reported acceptance criteria were met, but FDA explicitly limits promotional interpretation and the evidence does not establish patient outcomes.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
uCT 780 produces whole-body cross-sectional CT images, including head, neck, cardiac, and vascular imaging, supports protocol-governed low-dose lung cancer screening and dual-energy material visualization, and uses DELTA deep-learning reconstruction for adult head, chest, abdomen, cardiac, and vascular applications.
  • Exact FDA submission
  • Checked 2026-09-19

Clinical-use display mirrors the exact FDA-supported purpose reconciled from the decision-summary packet.

Workflow role
Acquires and reconstructs CT examinations, applies DELTA at one of five noise-reduction levels, and supports dual-energy analysis by combining low- and high-energy acquisitions of the same anatomy to visualize material or chemical information and multiple-energy images.
  • Exact FDA submission
  • Checked 2026-09-02
Required input
CT projection data acquired on uCT 780; uWS-CT-Dual Energy Analysis accepts United Imaging CT images of the same anatomy acquired at different tube voltages and currents.
  • Exact FDA submission
  • Checked 2026-09-19

Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

Output and clinician action
Cross-sectional CT images reconstructed with FBP or DELTA and dual-energy material, chemical, and multiple-energy visualizations for qualified-user review.
  • Exact FDA submission
  • Checked 2026-09-19

Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

Care setting
Professional healthcare facilities performing diagnostic CT, cardiac and vascular CT, dual-energy analysis, and protocol-governed lung cancer screening.
  • Exact FDA submission
  • Checked 2026-09-02
Intended users
A consultation with a radiologist and a physicist should be made to determine the appropriate dose to obtain diagnostic image quality for the particular clinical task; clinicians or dosimetrists should only be allowed to reduce patient dose in clinical practice.
  • Exact FDA submission
  • Checked 2026-09-19

This replaces the broader current clinician and imaging-staff label with the packet's direct dose-management user conditions.

Limitations
The FDA summary states that the submitted clinical study alone cannot support promotional claims that DELTA achieves equivalent or better image quality; additional testing is needed for such claims. A radiologist and physicist should determine appropriate dose for each diagnostic task, only clinicians or dosimetrists should reduce dose, and DELTA was not thoroughly tested in pediatric patients. Low-dose lung cancer screening must follow an approved and published screening program.
  • Exact FDA submission
  • Checked 2026-09-19

Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

Evidence summary
FDA-reviewed manufacturer evidence includes phantom testing and a 60-subject, two-reader clinical image-quality program with separated training, validation, and test data. The reported acceptance criteria were met, but FDA explicitly limits promotional interpretation and the evidence does not establish patient outcomes.
  • Exact FDA submission
  • Checked 2026-09-02

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
FDA-reviewed manufacturer evidence includes phantom testing and a 60-subject, two-reader clinical image-quality program with separated training, validation, and test data. The reported acceptance criteria were met, but FDA explicitly limits promotional interpretation and the evidence does not establish patient outcomes.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-02
Reported sensitivity
Research pending
  • Needs research
  • Exact FDA submission
  • Checked 2026-08-31

This field has not been curated yet.

Reported specificity
Research pending
  • Needs research
  • Exact FDA submission
  • Checked 2026-08-31

This field has not been curated yet.

DELTA mean CT-value difference, head

4 HU upper bound

  • EndpointAbsolute mean CT-value difference between DELTA and filtered back projection in head phantom testing
  • PopulationWater, Catphan, PBU-60, and MITA phantom testing applicable to the head protocol
  • Tested versionDELTA on uCT 780 cleared in K241079

DELTA mean CT-value difference, body

6 HU upper bound

  • EndpointAbsolute mean CT-value difference between DELTA and filtered back projection in body phantom testing
  • PopulationWater, Catphan, PBU-60, and MITA phantom testing applicable to body protocols
  • Tested versionDELTA on uCT 780 cleared in K241079

K241079 DELTA phantom performance testing

  • DesignManufacturer bench comparison of DELTA and filtered back projection using water, Catphan, PBU-60, and MITA phantoms
  • PopulationHead and body CT phantom protocols evaluating CT value, low-contrast detectability, image noise, dose, and high-contrast spatial resolution
  • Scopeexact submission
  • Tested versionDELTA on uCT 780 cleared in K241079
  • IndependenceSponsor or vendor study

K241079

All stated bench acceptance criteria were met; phantom results do not establish clinical outcomes.

K241079 DELTA clinical reader study

  • DesignManufacturer-sponsored image-quality study with two U.S. board-certified radiologists using five-point ratings for noise, structure fidelity, and overall image quality
  • Population60 subjects total: 20 validation cases with five each from abdomen, chest, head, and cardiac examinations, plus 40 test cases with ten per body part across different dose levels
  • Scopeexact submission
  • Tested versionDELTA on uCT 780 cleared in K241079
  • Samplen=60
  • IndependenceSponsor or vendor study

K241079

Training data were excluded from validation and test sets. FDA reports that criteria were met but explicitly states that this study alone cannot support promotional equivalence or superiority claims.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
FDA recall Z-0220-2026 affects uCT 780 systems. A third-party outer cover could become trapped between the patient table and gantry and interfere with table movement. FDA lists the recall as open and classified.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04

Each published event was manually matched to the exact FDA submission and affected product or version; a recall does not establish an AI-algorithm defect or current site exposure unless the event states that scope.

recall: Z-0220-2026

Open, Classified

2025-10-21

Exact uCT 780 system match. This is a mechanical and accessory-use issue; the FDA record does not identify an AI-algorithm defect.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not verified: Pricing information is recorded but not verified against a resolving source.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: CT projection data acquired on uCT 780; uWS-CT-Dual Energy Analysis accepts United Imaging CT images of the same anatomy acquired at different tube voltages and currents.

    Scope: Exact FDA submission. Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-19 · FDA K241079: uCT 780

  2. Routing

    Source context, not route validation: DELTA is deployed within the uCT 780 acquisition and image-processing software. The uWS dual-energy application consumes compatible United Imaging CT image sets acquired at two energy settings for the same anatomy.

    Scope: Exact FDA submission. Confirm DICOM services, workstation topology, PACS routing, series pairing, quantitative-map handling, licensing, and downstream compatibility for the installed release.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-02 · FDA K241079: uCT 780

  3. AI processing

    Source context, not route validation: On-premises uCT 780 CT scanner with embedded DELTA reconstruction and a compatible uWS workstation environment for dual-energy analysis.

    Scope: Exact FDA submission.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-02 · FDA K241079: uCT 780

  4. Returned objects

    Source context, not route validation: Cross-sectional CT images reconstructed with FBP or DELTA and dual-energy material, chemical, and multiple-energy visualizations for qualified-user review.

    Scope: Exact FDA submission. Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-19 · FDA K241079: uCT 780

  5. Viewer/worklist/report

    Unresolved route: Cross-sectional CT images reconstructed with FBP or DELTA and dual-energy material, chemical, and multiple-energy visualizations for qualified-user review.

    Scope: Exact FDA submission. Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-19 · FDA K241079: uCT 780

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
On-premises uCT 780 CT scanner with embedded DELTA reconstruction and a compatible uWS workstation environment for dual-energy analysis.
  • Exact FDA submission
  • Checked 2026-09-02
Integration
DELTA is deployed within the uCT 780 acquisition and image-processing software. The uWS dual-energy application consumes compatible United Imaging CT image sets acquired at two energy settings for the same anatomy.
  • Exact FDA submission
  • Checked 2026-09-02

Confirm DICOM services, workstation topology, PACS routing, series pairing, quantitative-map handling, licensing, and downstream compatibility for the installed release.

Security
United Imaging Healthcare's cybersecurity page lists a secure development lifecycle and controls: firewall, encrypted connections, OS hardening, antivirus, patches, authentication, audit log, disk and transmission encryption. Company-level, not release-specific.
  • Vendor-wide
  • Checked 2026-10-26

Vendor statement, not an attestation; exact-release scope is not established.

DELTA reconstruction controls

DELTA deep-learning reconstruction is embedded in uCT 780 acquisition and processing software for adult head, chest, abdomen, cardiac, and vascular CT and provides five selectable noise-reduction levels.

exact submission · checked 2026-09-02

Validate each protocol, dose target, reconstruction level, artifact pattern, and fallback with radiologist and physicist oversight before routine use.

Dual-energy analysis

uWS-CT-Dual Energy Analysis combines compatible low- and high-energy United Imaging CT image sets from the same anatomy to provide material, chemical, and multiple-energy visualizations.

exact submission · checked 2026-09-02

Confirm compatible acquisition protocols, workstation licensing, reconstruction parameters, quantitative validation, and export behavior.

Dose-governance requirement

The FDA summary directs sites to consult a radiologist and physicist for task-specific dose selection and limits dose reduction decisions to clinicians or dosimetrists.

exact submission · checked 2026-09-02

Include protocol approval, change control, pediatric restrictions, audit logging, and periodic image-quality review in implementation governance.

Current product-family context

United Imaging's current uCT 780 family page presents DELTA reconstruction and spectral and perfusion options, but commercial specifications and options may span configurations or software releases.

product family · checked 2026-09-02

Map every quoted feature, hardware option, interface, service level, and price to the exact installed configuration.

Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K241079
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
CT/CTA
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-19

The packet explicitly identifies uCT 780 as a computed tomography x-ray system; the current dossier modality is null. Controlled directory display reconciled from exact FDA wording: Computed tomography x-ray system. -> CT/CTA.

Anatomy
Multi-region
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-19

Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2025-01-07
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Human reviewedStatus
2026-09-04Last searched
25Fields reviewed
10Source classes checked
1Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

The refreshed discovery snapshot contains 1 PubMed and 0 ClinicalTrials.gov candidate record. Discovery metadata alone does not establish exact tested-product, version, population, and endpoint applicability, so all candidates remain quarantined and none was promoted. The current discovery snapshot contains 1 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. 1 FDA recall candidate was manually reviewed: 1 published and 0 rejected as a neighboring or otherwise inapplicable version. Native FDA recall identifiers produced 1 postmarket candidate record; 1 has been reviewed (1 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, fda device recall, vendor product page, fda decision summary packet, literature index, trial registry, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not verified - checked 2026-10-27 - Exact FDA submission

    No public price or quote for the exact K241079 configuration was established in this review.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-10-26 - Exact FDA submission

    Bounded web search on 2026-10-26 (query: "United Imaging uCT 780 reimbursement"; top results reviewed) found no vendor or payer page stating coding, coverage or payment for this product. This records what was found, not that none exists.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Installation timeline: Not yet reviewed
  • Training: Not verified - checked 2026-10-27 - Exact FDA submission

    Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.

  • Monitoring: Not verified - checked 2026-10-27 - Exact FDA submission

    Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.

8 sources - 3 history items

Source ledger

  1. FDA K241079: uCT 780

    U.S. Food and Drug Administration - Published 2025-01-07 - Accessed 2026-09-19

    Scope: purpose, anatomy, input, output, limitations, evidenceSummary, modality, intendedUsers, clinicalUse

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. FDA recall Z-0220-2026: Shanghai United Imaging Healthcare Co., Ltd. Computed Tomography X-ray System, Model:uCT 780 MD, Rx Only

    U.S. Food and Drug Administration - Published 2025-10-21 - Accessed 2026-09-04

    Scope: postmarketSafety, affectedProduct, recallStatus, correctiveAction

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. uCT 780 product-family page

    United Imaging Healthcare - Accessed 2026-09-02

    Scope: productFamily, implementationCapabilities, currentCommercialContext

  8. United Imaging Healthcare Cybersecurity

    United Imaging Healthcare - Accessed 2026-10-25

    Scope: security

Research history

  1. K241079 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    human reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K220961

Deep Learning Image Reconstruction

GE Healthcare Japan Corporation

TrueFidelity deep-learning CT reconstruction produces selectable-strength images for supported head, whole-body, cardiac, and vascular applications on the Discovery CT750 HD family.

Modality
CT/CTA
Anatomy
Multi-region
Decision
2022-07-29
FDA-cleared K212441

Philips Incisive CT

Philips Healthcare (Suzhou) Co., Ltd.

Philips Incisive CT provides head, whole-body, cardiac, and vascular CT imaging for patients of all ages and can support qualified low-dose lung screening under labeled programs and protocols.

Modality
CT/CTA
Anatomy
Multi-region
Decision
2022-04-27
FDA-cleared K213999

Deep Learning Image Reconstruction

GE Medical Systems, LLC.

TrueFidelity deep-learning CT reconstruction supports head, whole-body, cardiac, and vascular imaging on specified Revolution CT configurations with release-specific speed and image-quality updates.

Modality
CT/CTA
Anatomy
Multi-region
Decision
2022-02-18

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history